TIMESPAN - TIMESPAN

News

1 April 2022

Happy Birthday #1year

Today we celebrate #oneyear of successful and amazing #work within the TIMESPAN project. Thanks to all TIMESPAN partners for all your efforts you made so far! Let's keep on going! #ADHD#...

Read article …

Events

7 May 2022

TIMESPAN webinar at ADHD Europe

TIMESPAN coordinator Prof. Henrik Larsson from the Örebro University in Sweden gives a short webinar about the TIMESPAN project at ADHD Europe. 👉Watch the whole webinar here.

About

Emerging evidence points at a significant association and shared genetic traits between adult attention-deficit / hyperactivity disorder (ADHD) and cardiometabolic conditions such as obesity, type 2 diabetes, and cardiovascular disease, which, when inadequately treated, can lead to adverse outcomes and significant costs for society. Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. This is problematic given that ADHD is a common, serious, and complex chronic condition among adults. This is where TIMESPAN steps in, fostering improvements in risk stratification and of the treatments for patients with ADHD who also have a cardiometabolic disease.

Objectives

Determine if and how ADHD in adults worsens prognosis and hampers the management of cardiometabolic disease, leveraging the largest data sets and population registries available world-wide.
Identify the cardiometabolic risks and benefits of multidisciplinary treatment approaches in patients with ADHD, performing advanced pharmacological and epidemiological analyses on available data as well as acquiring new and unique real-world data using active and passive apps for smartphones and a groundbreaking new advanced smartwatch for continuous health monitoring.
Pinpoint reasons for ADHD treatment discontinuity in adult patients with and without cardiometabolic disease. Capitalizing on so far unused real-world clinician’s data through new algorithms, created utilizing Machine Learning (ML) and natural language processing techniques in conjunction with using state-of-the-art genomic approaches.
Discern patients with ADHD at high-risk for poor cardiometabolic outcomes and treatment discontinuity by applying novel AI driven methods like deep learning neural networks (DLNNs) on existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems.
Identify optimized and personalized treatment approaches across multiple disciplines, to minimize harm and maximize positive changes in disease prognosis and to improve treatment discontinuity.
Improve clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease.